Publications en collaboration avec des chercheurs de Hospital de la Santa Creu i Sant Pau (34)

2024

  1. Paired plasma lipidomics and proteomics analysis in the conversion from mild cognitive impairment to Alzheimer's disease

    Computers in Biology and Medicine, Vol. 176

2023

  1. Multiomics profiling of human plasma and cerebrospinal fluid reveals ATN-derived networks and highlights causal links in Alzheimer's disease

    Alzheimer's and Dementia, Vol. 19, Núm. 8, pp. 3350-3364

  2. Multivariate GWAS of Alzheimer’s disease CSF biomarker profiles implies GRIN2D in synaptic functioning

    Genome Medicine, Vol. 15, Núm. 1

2022

  1. Genome-Wide Association Study of Alzheimer’s Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer’s Disease Multimodal Biomarker Discovery Dataset

    Frontiers in Aging Neuroscience, Vol. 14

  2. Predicting AT(N) pathologies in Alzheimer’s disease from blood-based proteomic data using neural networks

    Frontiers in Aging Neuroscience, Vol. 14

  3. Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum

    JAMA Neurology, Vol. 79, Núm. 3, pp. 228-243

2021

  1. Accelerated long-term forgetting in individuals with subjective cognitive decline and amyloid-β positivity

    International Journal of Geriatric Psychiatry, Vol. 36, Núm. 7, pp. 1037-1049

  2. Accelerated long-term forgetting over three months in asymptomatic APOE ɛ4 carriers

    Annals of Clinical and Translational Neurology, Vol. 8, Núm. 2, pp. 477-484

  3. Plasma Proteomic Biomarkers Relating to Alzheimer’s Disease: A Meta-Analysis Based on Our Own Studies

    Frontiers in Aging Neuroscience, Vol. 13

  4. Replication study of plasma proteins relating to Alzheimer's pathology

    Alzheimer's and Dementia, Vol. 17, Núm. 9, pp. 1452-1464

  5. Sex-specific metabolic pathways were associated with alzheimer’s disease (Ad) endophenotypes in the european medical information framework for ad multimodal biomarker discovery cohort

    Biomedicines, Vol. 9, Núm. 11

  6. TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels

    Alzheimer's and Dementia, Vol. 17, Núm. 10, pp. 1628-1640

2020

  1. APOE ϵ4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer's disease

    Alzheimer's Research and Therapy, Vol. 12, Núm. 1

  2. Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology

    Journal of Alzheimer's Disease, Vol. 77, Núm. 3, pp. 1353-1368

  3. Genome-wide association study of Alzheimer’s disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset

    Translational Psychiatry, Vol. 10, Núm. 1

  4. Validation of plasma proteomic biomarkers relating to brain amyloid burden in the EMIF-Alzheimer's disease multimodal biomarker discovery cohort

    Journal of Alzheimer's Disease, Vol. 74, Núm. 1, pp. 213-225

2019

  1. A metabolite-based machine learning approach to diagnose Alzheimer-type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort

    Alzheimer's and Dementia: Translational Research and Clinical Interventions, Vol. 5, pp. 933-938

  2. Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum

    Alzheimer's and Dementia, Vol. 15, Núm. 5, pp. 644-654

  3. Changes in synaptic proteins precede neurodegeneration markers in preclinical Alzheimer’s disease cerebrospinal fluid*

    Molecular and Cellular Proteomics, Vol. 18, Núm. 3, pp. 546-560

  4. Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay

    Alzheimer's and Dementia, Vol. 15, Núm. 11, pp. 1478-1488